These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32228106)

  • 21. The role of drug-metabolizing enzymes in synthetic lethality of cancer.
    Zeng Z; Zheng W; Hou P
    Pharmacol Ther; 2022 Dec; 240():108219. PubMed ID: 35636517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics.
    Bhattacharjee S; Nandi S
    IUBMB Life; 2017 Dec; 69(12):929-937. PubMed ID: 29171189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-omics characterization of synthetic lethality-related molecular features: implications for SL-based therapeutic target screening.
    Weng S; Ruan H
    FEBS J; 2023 Mar; 290(6):1477-1480. PubMed ID: 36461713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complex synthetic lethality in cancer.
    Ryan CJ; Devakumar LPS; Pettitt SJ; Lord CJ
    Nat Genet; 2023 Dec; 55(12):2039-2048. PubMed ID: 38036785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
    Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
    Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The tumor therapy landscape of synthetic lethality.
    Zhang B; Tang C; Yao Y; Chen X; Zhou C; Wei Z; Xing F; Chen L; Cai X; Zhang Z; Sun S; Liu Q
    Nat Commun; 2021 Feb; 12(1):1275. PubMed ID: 33627666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets.
    Guo J; Liu H; Zheng J
    Nucleic Acids Res; 2016 Jan; 44(D1):D1011-7. PubMed ID: 26516187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
    Gerhards NM; Rottenberg S
    Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
    Stover EH; Konstantinopoulos PA; Matulonis UA; Swisher EM
    Clin Cancer Res; 2016 Dec; 22(23):5651-5660. PubMed ID: 27678458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
    Gao D; Herman JG; Guo M
    Oncotarget; 2016 Jun; 7(24):37331-37346. PubMed ID: 26967246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic Lethal Interactions in Cancer Therapy.
    Geng X; Wang X; Zhu D; Ying S
    Curr Cancer Drug Targets; 2017; 17(4):304-310. PubMed ID: 27113746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of PARP inhibitors in oncology.
    Rodon J; Iniesta MD; Papadopoulos K
    Expert Opin Investig Drugs; 2009 Jan; 18(1):31-43. PubMed ID: 19053880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A lethal combination for cancer cells: synthetic lethality screenings for drug discovery.
    Ferrari E; Lucca C; Foiani M
    Eur J Cancer; 2010 Nov; 46(16):2889-95. PubMed ID: 20724143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re-defining synthetic lethality by phenotypic profiling for precision oncology.
    Akimov Y; Aittokallio T
    Cell Chem Biol; 2021 Mar; 28(3):246-256. PubMed ID: 33631125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mapping the landscape of synthetic lethal interactions in liver cancer.
    Yang C; Guo Y; Qian R; Huang Y; Zhang L; Wang J; Huang X; Liu Z; Qin W; Wang C; Chen H; Ma X; Zhang D
    Theranostics; 2021; 11(18):9038-9053. PubMed ID: 34522226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP inhibition as a prototype for synthetic lethal screens.
    Liu X
    Methods Mol Biol; 2013; 986():123-37. PubMed ID: 23436410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of synthetic lethality anticancer therapeutics.
    Fang B
    J Med Chem; 2014 Oct; 57(19):7859-73. PubMed ID: 24893124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small Molecules Targeting DNA Polymerase Theta (POLθ) as Promising Synthetic Lethal Agents for Precision Cancer Therapy.
    Pismataro MC; Astolfi A; Barreca ML; Pacetti M; Schenone S; Bandiera T; Carbone A; Massari S
    J Med Chem; 2023 May; 66(10):6498-6522. PubMed ID: 37134182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.